The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was developed under a R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) based upon a measles vaccine vector technology.
